ASND vs. MRNA: A Head-to-Head Stock Comparison

Company Overview

With ASND at 9.55 billion USD and MRNA at 9.96 billion USD, their market capitalizations sit in the same ballpark.

MRNA carries a higher beta at 2.00, indicating it’s more sensitive to market moves, while ASND remains steadier at 0.40.

ASND trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while MRNA remains a standard domestic listing.

Performance Comparison

This chart compares the performance of ASND and MRNA over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ASND and MRNA based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

• Neither ASND nor MRNA turned a profit—both carry negative P/E ratios of -24.59 and -2.96, underscoring continued losses that pressure their valuations.
• ASND posts a negative forward PEG of -2.23, hinting at anticipated earnings decline, whereas MRNA at 0.11 has projections for stable or growing earnings.
• ASND has a negative P/B ratio of -44.27, indicating its liabilities exceed assets (negative equity). MRNA, with a P/B of 0.99, maintains positive shareholder equity.
• ASND and MRNA both consumed more free cash flow than they generated last year—P/FCF of -27.48 and -2.47, respectively—highlighting persistent liquidity pressure.

Dividend Comparison

Neither ASND nor MRNA currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.

Financial Strength Metrics Comparison

This section dives into the financial resilience of ASND and MRNA, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

• ASND’s quick ratio of 0.71 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas MRNA at 4.14 maintains a comfortable buffer of liquid assets.
• ASND has negative equity (debt-to-equity ratio -4.46), an unusual warning sign, while MRNA at 0.07 maintains a conventional debt-to-equity balance.
• Both ASND and MRNA report negative interest coverage ratios (-3.72, -207.17), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.